Kazia paxalisib colorectal cancer data
Analysis based on 7 articles · First reported Jul 20, 2026 · Last updated Sep 01, 2026
The positive preclinical data could boost investor sentiment for Kazia Therapeutics, potentially increasing its stock price as the company advances paxalisib into a Phase 2 trial. The news may also positively impact Merck & Co., whose Keytruda is part of the combination, and could influence the broader oncology immunotherapy market.
Kazia Therapeutics announced preclinical and translational data showing its lead asset, paxalisib, reduced tumor burden by 52% in MSS/pMMR colorectal cancer models, and adding paxalisib to an immunotherapy drug reduced tumor volume by an additional 50% compared to immunotherapy alone. The company also advanced a biomarker program and filed a new patent covering paxalisib's use in colorectal cancer. Kazia plans to launch a five-arm Phase 2 clinical trial evaluating paxalisib as monotherapy and in combination with pembrolizumab (Keytruda) versus standard of care in pre-treated MSS/pMMR metastatic colorectal cancer, with enrollment expected to begin in Q1 2027. The data suggests paxalisib may reprogram the tumor microenvironment to enhance immune visibility, potentially offering a first-in-class strategy for this patient population where checkpoint inhibitors have shown little benefit.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard